Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Rotigotine is a non-selective non-ergot dopaminergic D2 agonist used for the treatment of Parkinson's disease and restless legs syndrome. It has actions similar to those of bromocriptine. Administration in the form of transdermal patches every 24 hours.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (very large volume of distribution and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.
Being a dopamine agonist, it is very likely to decrease prolactin secretion. Milk production, once lactation is established, is not so much dependent on prolactin as on the frequency of breastfeeding or milk expression. (Messinis 1985)
If it is administered during lactation, it is advisable not to take it during the first postpartum month and to monitor milk production.